Depleting MET-expressing tumor cells by ADCC provides a therapeutic advantage over inhibiting HGF/MET signaling

Cancer Research

Volumn 75, Issue 16, 2015, Pages 3373-3383

  Hultberg, Anna ^a   Morello, Virginia ^b,c   Huyghe, Leander ^d   De Jonge, Natalie ^a   Blanchetot, Christophe ^a   Hanssens, Valérie ^a   De Boeck, Gitte ^a   Silence, Karen ^a   Festjens, Els ^a   Heukers, Raimond ^e   Roux, Benjamin ^f   Lamballe, Fabienne ^f   Ginestier, Christophe ^g   Charafe Jauffret, Emmanuelle ^g   Maina, Flavio ^f   Brouckaert, Peter ^d   Saunders, Michael ^a   Thibault, Alain ^a   Dreier, Torsten ^a   De Haard, Hans ^a   Michieli, Paolo ^b,c   more..

^a ArGEN X BVBA   (Belgium)

^b UNIVERSITY OF TURIN   (Italy)

^c IRCCS   (Italy)

^d GHENT UNIVERSITY   (Belgium)

^e UTRECHT UNIVERSITY   (Netherlands)

^f AIX MARSEILLE UNIVERSITÉ   (France)

^g AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGX 111; MONOCLONAL ANTIBODY; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ARGX-111; MET PROTEIN, HUMAN; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ARTICLE; BINDING COMPETITION; BREAST CARCINOMA; CANCER CELL LINE; CANCER STEM CELL; CELL SURFACE; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DEPLETION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; FEMALE; HUMAN; HUMAN CELL; LIGAND BINDING; METASTASIS INHIBITION; MOUSE; MOUSE MODEL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BINDING, COMPETITIVE; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE, NUDE; NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942844145     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0356     Document Type: Article

References (44)

1. Trusolino L, Bertotti A, Comoglio PM MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-48.
2. Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 588-610.
3. Birchmeier C, Birchmeier W, Gherardi E, Van de Woude GF. Met, metastasis, motility, and more. Nat Rev Mol Cell Biol 2003; 4: 915-25.
4. Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. J Clin Invest 2002; 109: 857-62.
5. Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 588-610.
6. Trusolino L, Comoglio PM Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002; 2: 289-300.
7. To CT, Tsao MS The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers. Oncol Rep 1998; 5: 1013-24.
8. You WK, McDonald DM The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 2008; 41: 833-9.
9. Gherardi E, Birchmeier W, Birchmeier C., Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89-103.
10. Cappuzzo F, Marchetti A, Skokan M., Rossi E, Gajapathy S, Felicioni L., et al. Increased MET gene copy number negatively affects survival of surgically resected non-small cell lung cancer patients. J Clin Oncol 2009; 27: 1667-74.
11. De Oliveira A.T., Matos D, Logullo A.F., DA Silva SR, Neto RA, Filho AL, et al. MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res 2009; 29: 4807-11.
12. Zagouri F, Bago-Horvath Z, Rössler F, Brandstetter A., Bartsch R, Papadimitriou CA, et al High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 2013; 108: 1100-5.
13. Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 2008; 98: 1102-8.
14. Graziano F, Galluccio N, Lorenzini P., Ruzzo A, Canestrari E, D'Emidio S, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011; 29: 4789-95.
15. Rocci A, Gambella M, Aschero S., Baldi I, Trusolino L, Cavallo F., et al. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. Br J Haematol 2014; 164: 841-50.
16. Olmez OF, Cubukcu E, Evrensel T., Kurt M, Avci N, Tolunay S., et al. The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme. Clin Transl Oncol 2014; 16: 173-7.
17. Underiner TL, Herbertz T, Miknyoczki SJ Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med Chem 2010; 10: 7-27.
18. Cecchi F, Rabe DC, Bottaro DP Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 553-572.
19. Smyth EC, Sclafani F, Cunningham D. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 2014; 7: 1001-1014.
20. Bertotti A, Burbridge MF, Gastaldi S, Galimi F., Torti D, Medico E, et al Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal 2009; 2: ra80.
21. Lai AZ, Cory S, Zhao H., Gigoux M, Monast A, Guiot M.C., et al. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer. Sci Signal 2014; 7: ra38.
22. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-516.
23. Michieli P, Cavassa S, Basilico C., De Luca A, Mazzone M, Asti C., et al. An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nat Biotechnol 2002; 20: 488-495.
24. Basilico C, Hultberg A, Blanchetot C., de Jonge N, Festjens E, Hanssens V., et al. Four individually druggable MET hotspots mediate HGF-driven tumor progression. J Clin Invest 2014; 124: 3172-3186.
25. Charafe-Jauffret E., Ginestier C, Bertucci F., Cabaud O, Wicinski J, Finetti P., et al. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res 2013; 73: 7290-7300.
26. Armour KL, Clark MR, Hadley A.G., Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999; 29: 2613-2624.
27. Lazar GA, Dang W, Karki S., Vafa O, Peng JS, Hyun L, et al Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103: 4005-4010.
28. Martens T, Schmidt NO, Eckerich C, Fillbrandt R., Merchant M, Schwall R, et al A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12: 6144-6152.
29. Pennacchietti S, Cazzanti M, Bertotti A., Rideout WM III, Han M, Gyuris J, et al. Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. Cancer Res 2014; 74: 6598-6609.
30. Vaccaro C, Bawdon R, Wanjie S., Ober RJ, Ward ES. Divergent activitiesofan engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A 2006; 103: 18709-18714.
31. Masuda K, Kubota T, Kaneko E., Iida S, Wakitani M, Kobayashi-Natsume Y, et al. Enhanced binding affinity for FcgammaRIII of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol 2007; 44: 3122-3131.
32. Basilico C, Pennacchietti S, Vigna E., Chiriaco C, Arena S, Bardelli A., et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013; 19: 2381-2392.
33. Iqbal J, Chong PY, Tan PH Breast cancer stem cells: an update. J Clin Pathol 2013; 66: 485-490.
34. Parekh BS, Berger E, Sibley S., Cahya S, Xiao L, LaCerte M.A., et al. Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs 2012; 4: 310-318.
35. Smolen GA, Sordella R, Muir B., Mohapatra G, Barmettler A, Archibald H., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006; 103: 2316-2321.
36. McDermott U, Sharma SV, Dowell L, Greninger P., Montagut C, Lamb J, et al Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007; 104: 19936-19941.
37. Lim YC, Kang HJ, Moon JH C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Oral Oncol 2014; 50: 633-639.
38. Luraghi P, Reato G, Cipriano E., Sassi F, Orzan F, Bigatto V., et al. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res 2014; 74: 1857-1869.
39. Nishida S, Hirohashi Y, Torigoe T., Inoue R, Kitamura H, Tanaka T., et al. Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor. Cancer Sci 2013; 104: 431-436.
40. Baccelli I, Schneeweiss A, Riethdorf S., Stenzinger A, Schillert A, Vogel V., et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539-544.
41. De Bacco F., Casanova E, Medico E., Pellegatta S, Orzan F, Albano R., et al. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 2012; 72: 4537-4550.
42. Meacham CE, Morrison SJ Tumour heterogeneity and cancer cell plasticity. Nature 2013; 501: 328-337.
43. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714-726.
44. Parikh RA, Wang P, Beumer J.H., Chu E., Appleman LJ. The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. OncoTargets Ther 2014; 7: 969-983.